{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:15:14Z","timestamp":1793646914278,"version":"4.5.1"},"reference-count":41,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.2169\/internalmedicine.0492-17","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T18:23:32Z","timestamp":1522347812000},"page":"2443-2450","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease"],"prefix":"10.2169","volume":"57","author":[{"given":"Ryota","family":"Niikura","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoku","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Japan Association for Development of Community Medicine Nerimahikarigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Endoscopy and Endoscopic Surgery, The University of Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54: 710-717, 2005.","DOI":"10.1136\/gut.2004.051821"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 44: 518-534, 2009.","DOI":"10.1007\/s00535-009-0047-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 51: 751-767, 2016.","DOI":"10.1007\/s00535-016-1227-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Habu Y, Maeda K, Kusuda T, et al.  &quot;Proton-pump inhibitor-first&quot; strategy versus &quot;step-up&quot; strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol 40: 1029-1035, 2005.","DOI":"10.1007\/s00535-005-1704-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 5: CD002095, 2013.","DOI":"10.1002\/14651858.CD002095.pub5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tew S, Jamieson GG, Pilowsky I, Myers J. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 10: 9-15, 1997.","DOI":"10.1093\/dote\/10.1.9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Richter JE, Kovacs TO, Greski-Rose PA, Huang section sign B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 13: 795-804, 1999.","DOI":"10.1046\/j.1365-2036.1999.00558.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 45: 413-421, 2010.","DOI":"10.1007\/s00535-009-0173-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med 49: 1469-1476, 2010.","DOI":"10.2169\/internalmedicine.49.3615"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Anvari M, Allen C, Marshall J, et al. A randomized controlled trial of laparoscopic nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov 13: 238-249, 2006.","DOI":"10.1177\/1553350606296389"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gillies RS, Stratford JM, Booth MI, Dehn TC. Does laparoscopic antireflux surgery improve quality of life in patients whose gastro-oesophageal reflux disease is well controlled with medical therapy? Eur J Gastroenterol Hepatol 20: 430-435, 2008.","DOI":"10.1097\/MEG.0b013e3282f47995"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tokudome K, Funaki Y, Sasaki M, et al. Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant, non-erosive esophagitis. World J Gastroenterol 18: 5940-5947, 2012.","DOI":"10.3748\/wjg.v18.i41.5940"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43: 240-251, 2016.","DOI":"10.1111\/apt.13461"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 33: 1140-1157, 2016.","DOI":"10.1007\/s12325-016-0345-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43: 1048-1059, 2016.","DOI":"10.1111\/apt.13588"},{"key":"16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"16. Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 95: 156-161, 2017.","journal-title":"Digestion","ISSN":"https:\/\/id.crossref.org\/issn\/0012-2823","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kawamura O, Hosaka H, Shimoyama Y, et al. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. Digestion 91: 19-25, 2015.","DOI":"10.1159\/000368766"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tamura Y, Funaki Y, Izawa S, et al. Pathophysiology of functional heartburn based on Rome III criteria in Japanese patients. World J Gastroenterol 21: 5009-5016, 2015.","DOI":"10.3748\/wjg.v21.i16.5009"},{"key":"19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gut.2007.133470","volume":"57","author":"F Zerbib","year":"2008","unstructured":"19. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 57: 156-160, 2008.","journal-title":"Gut","ISSN":"https:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawami N, Takenouchi N, Umezawa M, et al. Pathogenesis of double-dose proton pump inhibitor-resistant non-erosive reflux disease, and mechanism of reflux symptoms and gastric acid secretion-suppressive effect in the presence or absence of <i>Helicobacter pylori<\/i> infection. Digestion 95: 140-145, 2017.","DOI":"10.1159\/000455834"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 30: 1030-1038, 2009.","DOI":"10.1111\/j.1365-2036.2009.04142.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jonasson C, Wernersson B, Hoff DA, Hatlebakk JG. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 37: 564-572, 2013.","DOI":"10.1111\/apt.12204"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Jonasson C, Moum B, Bang C, Andersen KR, Hatlebakk JG. Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Aliment Pharmacol Ther 35: 1290-1300, 2012.","DOI":"10.1111\/j.1365-2036.2012.05092.x"},{"key":"24","unstructured":"24. Wang K, Duan LP, Ge Y, Xu ZJ, Xia ZW. Diagnostic values of GerdQ, 24 hours ambulatory oesophageal pH and impedance-pH monitoring in Barrett&apos;s esophagus, reflux esophagitis and non-erosive reflux disease. Zhonghua Yi Xue Za Zhi 91: 1228-1232, 2011 (in Chinese, Abstract in English)."},{"key":"25","unstructured":"25. Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther 25: 143-153, 2007."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kohata Y, Fujiwara Y, Watanabe T, et al. Long-term benefits of smoking cessation on gastroesophageal reflux disease and health-related quality of life. PLoS One 11: e0147860, 2016.","DOI":"10.1371\/journal.pone.0147860"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 3: 87-97, 1969.","DOI":"10.1055\/s-0028-1098086"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Koike K. Association between gastric cancer and the Kyoto classification of gastritis. J Gastroenterol Hepatol 32: 1581-1586, 2017.","DOI":"10.1111\/jgh.13764"},{"key":"29","unstructured":"29. Greenland S. Applications of stratified analysis methods. In: Modern Epidemiology. 3rd ed. Greenland S, Rothman KJ, Lash TL, Eds. Lippincott Williams and Wilkins, Philadelphia, PA, 2008: 283-302."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol 6: e94, 2015.","DOI":"10.1038\/ctg.2015.18"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori<\/i> eradication: a phase III, randomised, double-blind study. Gut 65: 1439-1446, 2016.","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against <i>Helicobacter pylori<\/i>: a multicenter retrospective study in clinical practice. J Dig Dis 17: 670-675, 2016.","DOI":"10.1111\/1751-2980.12398"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: Efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers-results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther 45: 240-252, 2017.","DOI":"10.1111\/apt.13876"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep 6: 175-180, 2017.","DOI":"10.3892\/br.2016.828"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomised open-label cross-over study. Aliment Pharmacol Ther 42: 719-730, 2015.","DOI":"10.1111\/apt.13325"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Furuta T, Shimatani T, Sugimoto M, et al. Acid-Related Symptom Research Group (2011) Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol 46: 1273-1283, 2011.","DOI":"10.1007\/s00535-011-0446-2"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 17: 274-278, 2004.","DOI":"10.1111\/j.1442-2050.2004.00424.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease-a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33: 323-332, 2011.","DOI":"10.1111\/j.1365-2036.2010.04517.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Tominaga K, Iwakiri R, Fujimoto K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol 47: 284-292, 2012.","DOI":"10.1007\/s00535-011-0488-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp 81-82: 1-7, 2016.","DOI":"10.1016\/j.curtheres.2016.12.001"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Hallas J, Pottegard A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med 275: 581-589, 2014.","DOI":"10.1111\/joim.12186"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/17\/57_0492-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T01:36:00Z","timestamp":1535765760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/17\/57_0492-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0492-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}